endpts.com Open in urlscan Pro
108.138.36.96  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * Editorial Standards
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



EyeBio CEO David Guyer (L) and CSO Anthony Adamis
November 14, 2023 10:40 AM ESTUpdated 12:06 PM
Financing
Startups


EYE­BIO DOU­BLES THE SIZE OF ITS SE­RIES A AS AN­TI-VEGF VET­ER­ANS SEEK NEW
WAYS OF TREAT­ING RETI­NAL DIS­EASES


KYLE LAHUCIK

SENIOR REPORTER

Reti­nal dis­ease biotech Eye­Bio has dou­bled the size of its ini­tial Se­ries
A raise from Feb­ru­ary 2022. With an­oth­er $65 mil­lion, the biotech will
fur­ther test its Wnt ag­o­nist and bring a sec­ond as­set in­to the clin­ic
next year, CEO David Guy­er told End­points News on Tues­day morn­ing.

The Se­ries A ex­ten­sion ar­rives a few weeks af­ter the field’s biggest
con­fab, the Amer­i­can Acad­e­my of Oph­thal­mol­o­gy an­nu­al meet­ing, and
comes af­ter a string of fi­nanc­ing rounds that has buoyed oth­er star­tups in
the space.


UNLOCK THIS ARTICLE INSTANTLY BY BECOMING A FREE SUBSCRIBER.

You’ll get access to free articles each month, plus you can customize what
newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS


ASSOCIATE DIRECTOR, OPERATIONS (LABORATORY SETTING)

ADIMAB, LLC

LEBANON, NH, USA

view job offer post your job now
TRENDING NOW


FDA AP­PROVES VER­TEX AND CRISPR'S CAS­GEVY AS FIRST CRISPR-EDIT­ED THER­A­PY
FOR BE­TA-THA­LASSEMIA


HOW PHAR­MA GI­ANTS LIKE GSK AND BRIS­TOL MY­ERS ARE US­ING TECH TO SHAPE THEIR
FU­TURE


NO­VO NORDISK RESTARTS AD­VER­TIS­ING FOR OBE­SI­TY DRUG WE­GOVY WITH NEW
CAM­PAIGN


AM­I­CUS BRIEFS FLY IN AS IRA 'FAIR PRICE' DEAD­LINE LOOMS


A DECADE AF­TER ITS FIRST FDA AP­PROVAL, TAKE­DA EX­PANDS LA­BEL OF HYQVIA TO
IN­CLUDE RARE AU­TOIM­MUNE DIS­OR­DER

sponsored


BIOTECH: A NEW PATH TO CAP­I­TAL RAIS­ING IN PUB­LIC AND PRI­VATE MAR­KETS

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * Editorial Standards
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2024

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET



BREAKING NEWS ALERTS 2-3 times a week


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.